English
French
English
French
About Us
Medication Returns Program
Operations
Our Products
Programs
Contact
NATCO transfers Lenalidomide ANDA to Arrow
Home
NATCO Global
NATCO transfers Lenalidomide ANDA to Arrow
August 4, 2021
natcopharma-wpdmn
No Comments
NATCO transfers Lenalidomide ANDA to Arrow
Read more >
Prev Post
NATCO receives approval for Carfilzomib Vials ANDA (generic for KYPROLIS
®
) in the US market
Next Post
Natco Pharma (Canada) Inc. announces the launch of
Pr
NAT-LENALIDOMIDE Capsules, the first generic alternative to Revlimid
®
Leave a Reply
Cancel reply
Your name *
Your email *
Save my name, email, and website in this browser for the next time I comment.
Comments *
Post Comment
×
